Skip to main content

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Available now, this new proprietary dispensing capability lets customers order the exact single-use bag sizes and quantities their process requires, released as a single lot with one Certificate of Analysis, with no added turnaround time

HOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today introduced the Fill-Tek™ Dispensing System. Fill-Tek is a proprietary single-use bag dispensing capability that fills an entire custom reagent order across multiple bag sizes and quantities as a single lot. The Fill-Tek system removes the per-bag-size minimums that come with fixed manifold designs, so manufacturers can order the formats their process calls for rather than the formats the fill line requires.

“Your process is one of a kind, and now your fill line can be, too,” said Stephen Gunstream, President and Chief Executive Officer. “Our new Fill-Tek Dispensing System is the latest evolution of our modular manufacturing platform, expanding our ability to truly meet our customers’ complex custom reagent needs. Previously, fixed manifold designs could constrain the number of single-use bags that could be filled as one lot. Our talented team of engineers developed Fill-Tek to remove that constraint entirely. Following the recent introduction of our AI-driven Build-Tek™ Custom Configurator, the launch of Fill-Tek demonstrates our team’s commitment to continued innovation across the entire custom order process to meet the ever-changing needs of our customers who develop and manufacture emerging therapies and diagnostics.”

With the Fill-Tek Dispensing System, customers can simply specify the various bag sizes and quantities across formats ranging from 250 mL to 200 L single-use bags, and then tailor fill volume, number, size, and sequence of QC samples, testing requirements, and connectors. Fill-Tek uses validated aseptic welds to connect the customer’s specific combination of single-use bags to a dispensing vessel so they can be filled from a single batch through a single filter, resulting in one Certificate of Analysis for each lot.

“The bioprocessing workflows and manufacturing requirements for novel therapeutics and diagnostics are complex and dynamic, and we’re committed to finding better ways to streamline and support them. Fill-Tek operates by formulating and dispensing from one batch vessel through one filter into the exact configurations that a customer may need, including a variety of bag sizes with different fill volumes, or even a single bag,” said Bella Neufeld, Teknova’s Vice President of Operations. “With Fill-Tek, we simplify incoming quality control requirements, enable the use of the same reagent in different volumes at different workflow stages, and minimize rework by attaching the right connectors onto the bags so they seamlessly integrate into an existing bioprocessing system.”

Fill-Tek runs in Teknova’s ISO-classified cleanrooms as part of the Company’s validated aseptic dispensing process, backed by its ISO 13485:2016 certified quality management system. The capability is available across Teknova’s RUO, RUO+, and GMP manufacturing grades, with batch volumes that start from eight liters for custom research-grade orders and 25 liters for GMP-grade orders, scaling up to 2,000 liters – all with no change to Teknova’s industry-leading turnaround times.

Fill-Tek is available today. To place a custom order, customers can use the Build-Tek Custom Configurator on Teknova’s website, email info@teknova.com, or call 1.800.209.4488.

For more information about the Fill-Tek Dispensing System, click here.

ABOUT TEKNOVA

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

This press release was published by a CLEAR® Verified individual.

CONTACT: CONTACTS

Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100

Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.